Toolgen Incorporated
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Feb 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 6, 2026The maintenance fee for Platform for Expressing Protein of Interest in Liver (US 11,667,934) comes due Dec 6, 2026. Unpaid by Jun 7, 2027, it lapses early.
- 2 fees due Jun 19 to 30, 2027 · next Jun 19
- 1 fee due Sep 5, 2027The maintenance fee for Method for Identifying DNA Base Editing by Means of Cytosine Deaminase (US 11,920,151) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Nov 3 US 12,781,208 Streptococcus Pyogenes-Derived CAS9 Variant
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,809,839 | Method for concentrating cells that are genetically altered by nucleases In force · USPTO record | In force | USPTO record | |
| US 10,851,380 | Methods for Cleaving a Target DNA Using a Guide RNA Specific for the Target DNA and Cas Protein-Encoding Nucleic Acid or Cas Protein In force · Medium confidence | In force | Medium confidence | |
| US 12,473,559 | Cas9/RNA Complexes for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells In force · High confidence | In force | High confidence | |
| US 12,606,832 | Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells In force · High confidence | In force | High confidence | |
| US 12,612,632 | Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells In force · High confidence | In force | High confidence | |
| US 12,612,633 | Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells In force · High confidence | In force | High confidence | |
| US 12,612,634 | Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells In force · High confidence | In force | High confidence | |
| US 10,519,454 | Genome Editing Using Campylobacter Jejuni CRISPR/Cas System-Derived Rgen In force · High confidence | In force | High confidence | |
| US 12,509,697 | Oleic Acid -Enriched Plant Body Having Genetically Modified FAD2 and Production Method Thereof In force · High confidence | In force | High confidence | |
| US 12,286,635 | Oleic Acid-Enriched Plant Body Having Genetically Modified FAD2 and Production Method Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 27: 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
17 pending · 20 abandoned · 4 no status recorded
Showing 1 to 10 of 41, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page.
| Application | Title | Filed | Status |
|---|---|---|---|
| 19/015,836 | Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells | Jan 10, 2025 | Pending |
| 19/013,018 | Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells | Jan 8, 2025 | Pending |
| 18/944,148 | Cells for Intravascular Transplantation Having Hemocompatibility, Method of Producing Same, and Use Thereof | Nov 12, 2024 | Pending |
| 18/822,009 | Hypoimmunogenic Stem Cells, Hypoimmunogenic Cells Differentiated or Derived from Stem Cells and Method of Preparing Same | Aug 30, 2024 | Pending |
| 18/657,145 | Manipulated Immunoregulatory Element and Immunity Altered Thereby | May 7, 2024 | Pending |
| 18/590,251 | Vector for Delivering Active Agent to Nervous System, and Use Thereof | Feb 28, 2024 | Pending |
| 18/424,920 | Hemocompatible Mesenchymal Stem Cells, Preparation Method Therefor and Use Thereof | Jan 29, 2024 | Pending |
| 18/407,597 | Mesenchymal Stem Cell Having Oxidative Stress Resistance, Preparation Method Therefor, and Use Thereof | Jan 9, 2024 | Abandoned |
| 18/467,967 | Compositions Comprising Cas9/guide RNA Complexes for Inducing Targeted Disruption of Endogenous Genes in Eukaryotic Cells | Sep 15, 2023 | Abandoned |
| 18/314,050 | Composition for Cleaving a Target DNA Comprising a Guide RNA Specific for the Target DNA and Cas Protein-Encoding Nucleic Acid or Cas Protein, and Use Thereof | May 8, 2023 | Abandoned |
10 of 41 applications shown.
Pro members see all 41 published applications.